Mucoflem

Quick links to important sections

Mucoflem

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mucoflem

Property Description
Active Ingredient Carbocisteine (Carbocysteine)
Form Oral solution, Syrup, Capsules
Pharmacological Class Mucolytic and Mucoregulator
General Use Addressing thick, viscous mucus
Origin Synthetic (Cysteine derivative)

What Type of Medicine is Mucoflem and What is its Composition?

Mucoflem is a product based on the active substance Carbocisteine, which is classified as both a mucolytic agent and a mucoregulator, designed to modify the physical properties of bronchial secretions. The active ingredient is formally known by its International Nonproprietary Name (INN), Carbocisteine, or its synonym, Carbocysteine, which is structurally defined as S-Carboxymethyl-L-cysteine.

This compound is a synthetic derivative of the amino acid L-cysteine and is a single active substance preparation. It is administered via the oral route and is commonly available in several convenient dosage forms, notably a syrup or oral solution, which often includes flavorings to facilitate administration to the target patient groups, including both adults and children.

How Does Mucoflem Affect Mucus Viscosity?

The general purpose of Carbocisteine is to assist the body in clearing excessively thick or viscous mucus from the respiratory tract, an action recognized for helping to relieve respiratory congestion.

Carbocisteine exerts a dual action by both thinning existing mucus and influencing future mucus quality. Carbocisteine functions by regulating the mucin biosynthesis within the respiratory lining. This unique mechanism serves to directly reduce the viscosity and elasticity of the bronchial secretions. By making the phlegm thinner and more mobile, the medicine facilitates the efficient clearance of accumulated secretions, thereby supporting the natural mucociliary transport system and promoting improved respiratory comfort.

What side effects are possible with Mucoflem?

Possible Side Effects and Safety Information

The official safety information for Carbocisteine (the active ingredient in Mucoflem) focuses primarily on documented adverse reactions within the Gastrointestinal and Skin and subcutaneous tissue System-Organ Classes. Many of the reported effects, including serious reactions, are often classified in regulatory documents with a frequency of Not Known, meaning the occurrence rate cannot be accurately estimated from the available data.


Documented Adverse Reaction Patterns

Adverse reactions commonly listed in regulatory documents include gastrointestinal disorders such as nausea, vomiting, diarrhoea, and epigastric discomfort. Skin reactions are also documented, including various rashes and allergic skin eruptions.

Serious Safety Considerations

The regulatory label explicitly documents the possibility of serious adverse reactions. These include Gastrointestinal bleeding and Severe Cutaneous Adverse Reactions (SCARs), such as Stevens–Johnson syndrome and Erythema multiforme, which are typically reported with a frequency of Not Known.


Safety Restrictions and Contraindications

Official safety documents define specific limitations on the use of Carbocisteine. It is contraindicated in patients with active peptic ulceration due to the risk of gastrointestinal bleeding. Caution is advised for use in patients with a history of gastroduodenal ulcers or when taken concurrently with other medicines known to cause gastrointestinal bleeding. Furthermore, the product is contraindicated for use in children under two years of age. Use during pregnancy and lactation is generally not recommended as a precaution due to insufficient safety data.

Overdose and Emergency Response

The official regulatory documents for Carbocisteine (Mucoflem) provide specific information regarding overdosage, focusing on the expected clinical presentation and the mandatory emergency response.

Documented Manifestations and Severe Outcomes

The most probable clinical presentation of an overdosage is gastrointestinal disturbance. Officially documented signs include gastralgia (stomach pain), nausea, vomiting, and diarrhoea. While these are the primary symptoms, regulatory guidance underscores that any evidence of more severe outcomes, particularly signs of gastrointestinal bleeding, constitutes a critical trigger for immediate medical intervention.

Required Emergency Action and Management

Regulatory authorities mandate that in the event of a suspected overdose, the patient must seek immediate medical attention. This instruction explicitly requires the patient to go to a hospital casualty department straight away, ensuring the medicine container is taken for the treating physician's reference. The established management approach is defined as symptomatic and supportive treatment, as no specific antidote is known. Officially described supportive measures may include consideration of gastric lavage, which must be followed by clinical observation by medical staff. Furthermore, specific national health guidance applies to children under 5 years who have taken too much of the product, necessitating contact with emergency advice lines.

Therapeutic Uses of Mucoflem

What Mucoflem Treats: Main Uses and Benefits

Mucoflem (Carbocisteine) may be part of symptomatic management for respiratory conditions characterized by the symptoms related to the production of highly viscous and excessive mucus. The medicine is relevant for use in the adjunctive therapy of respiratory tract disorders involving this hypersecretion.

This medication is commonly applied in the management of chronic conditions, including Chronic Obstructive Pulmonary Disease (COPD), Chronic Bronchitis, and bronchiectasis. It is relevant when symptoms cluster into patterns of persistent, difficult-to-clear phlegm. When applied, it may be part of a supportive strategy used for conditions where symptoms are related to recurrent or episodic manifestations linked to mucus accumulation, offering symptomatic relief that helps patients cope more steadily.

“It is commonly used to help with managing symptoms of impaired airway clearance, supporting patients during difficult episodes.”

By addressing the symptoms related to the thickened, dense mucus, the medicine is commonly used to help with managing symptoms of impaired airway clearance that result in an often ineffective productive cough and chest congestion. This application supports patients during episodes of heightened discomfort by assisting with maintaining functional stability when symptoms interfere with routine activities. The use of this medication is considered relevant for managing the symptoms of respiratory disorders in a wide range of patients, including adults, older patients, and children (where appropriate).


Quick Fact: Symptomatic Support for Viscous Secretions

Mucoflem is applied in scenarios where excessive, dense sputum creates noticeable physiological strain and respiratory congestion, providing symptomatic relief that helps ease the overall symptom burden.

Eligibility and Restrictions for Use

Official Eligibility and Restrictions for Mucoflem (Carbocisteine)

The use of Mucoflem (Carbocisteine) is strictly defined by regulatory guidelines concerning a patient’s age, existing medical conditions, and physiological state. The information below reflects the official population eligibility classifications.

Absolute Contraindications (Must Not Use)

The medicine is contraindicated and must not be used by individuals with active peptic ulceration (gastric or duodenal) or known hypersensitivity to Carbocisteine or any product excipients. Contraindication also applies to children under 2 years of age, establishing a mandatory minimum age for use.

Age-Related Eligibility

The medicine is generally approved for use in children from 2 years old, adolescents, and adults. Caution is advised for elderly patients, particularly those with a history of gastroduodenal ulcers.

Physiological and Comorbidity Limitations

Use is not recommended for women who are pregnant (especially during the first trimester) or who are breastfeeding, due to limited data on human safety. Furthermore, regulatory labels recommend caution for any patient with a history of gastroduodenal ulcers. Specific use restrictions also apply to individuals with certain hereditary metabolic disorders, depending on the excipients present in the specific formulation (e.g., lactose or sorbitol content).

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interaction Scope

Property Official Regulatory Information
Medicinal product categories with documented interactions: Antitussives (cough suppressants); Medicines that inhibit bronchial secretions; Medicines known to cause gastrointestinal bleeding (e.g., Non-Steroidal Anti-Inflammatory Drugs).
Mechanistic basis of interactions (only if stated in label): Pharmacodynamic antagonism (opposing effects); Additive risk (increased risk of gastrointestinal bleeding).
Timing-based interaction rules (if applicable): None documented.
Population-specific interaction notes (if applicable): Increased caution is advised for co-administration of Carbocisteine and medicines known to cause gastrointestinal bleeding in elderly patients and those with a history of gastroduodenal ulcers.
Interaction-related restrictions: Co-administration with antitussives and anti-secretory agents is not recommended.

Official Interaction Statements

Official regulatory documents advise on specific co-administration restrictions for Carbocisteine based on functional conflicts and cumulative risk.

  • Co-administration with antitussives (cough suppressants) is not recommended because inhibiting the cough reflex may obstruct the intended effect of thinning and mobilizing bronchial secretions.
  • Co-administration with medicines that inhibit bronchial secretions (such as atropine-like drugs) is not recommended as these substances oppose the primary mucolytic action.
  • The use of Carbocisteine concomitantly with medicines known to cause gastrointestinal bleeding requires caution, particularly for elderly patients and individuals with a history of gastroduodenal ulcers due to a potentially heightened additive risk.

Connection to the Overall Interaction Profile

The regulatory profile highlights a structure based on pharmacodynamic conflicts and additive risk, setting restrictions against medicines that functionally oppose mucus clearance or increase the likelihood of gastrointestinal bleeding. There are generally no significant pharmacokinetic (CYP or transporter-mediated) interactions documented in the official prescribing information.

Mechanism of Action

Biochemical Modulation of Mucus Structure

Mucoflem (Carbocisteine) primarily acts as a mucolytic agent through its interaction with the respiratory secretions. The molecule directly functions by cleaving disulfide bonds that cross-link the large glycoprotein chains (mucins) within the mucus polymer. This chemical modification significantly reduces the viscosity and elasticity of the secretions, resulting in reduced adhesion and modified flow characteristics of the respiratory secretions.

Cellular Regulation and Redox Modulation

At the cellular level, the compound influences mucus biosynthesis within goblet cells by modulating enzyme activity, leading to a shift toward a lower viscosity profile. This is achieved by increasing the ratio of sialomucins (less viscous) relative to fucomucins (thicker). Furthermore, Mucoflem exhibits anti-oxidant capacity by scavenging reactive oxygen species (ROS) in the airway epithelium. This process influences key signaling pathways, contributing to the modulation of inflammatory mediators and downstream transcription of pro-inflammatory signals.

Dosage and Administration Information

How to Use Mucoflem

Mucoflem, which contains Carbocisteine, is administered via the oral route and is available in formulations such as hard capsules and various strengths of oral solution or syrup. The administration protocol is typically defined by a dual-phase dosing pattern and adherence to specific age-group instructions.


Official Dosing and Frequency Patterns

The standard adult regimen, which also applies to older adults, begins with a higher initial daily dose of 2250 mg of Carbocisteine. Once a satisfactory response has been achieved, this is reduced to a maintenance dose of 1500 mg per day. The total daily amount is administered in divided doses, generally taken three times a day.

Population Typical Daily Dose Structure Frequency Pattern
Adults & Elderly Initial: 2250 mg; Maintenance: 1500 mg Divided doses, typically three times daily
Children 5 to 12 Years Based on 250 mg/5 ml oral solution Three times daily
Children 2 to 5 Years Based on 250 mg/5 ml oral solution Four times daily

Administration and Timing Constraints

The medicine can be taken with or without food; however, some protocols suggest administration outside of mealtimes to ensure even spacing of doses. When using the liquid form, a dosing device must be used for accurate measurement, as kitchen spoons are not standardized for pharmaceutical dosage.

If a dose is missed, it should be taken as soon as it is remembered, unless the time for the next scheduled dose is near, in which case the missed dose should be skipped entirely to avoid taking a double dose. Treatment may be used for a short course in acute scenarios or as long-term supportive therapy for chronic conditions, depending on the clinical context.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Mucoflem (Carbocisteine)

Evidence for Use in Chronic Bronchitis and COPD

The most comprehensive research on Carbocisteine was studied for the long-term management of Chronic Obstructive Pulmonary Disease (COPD) and chronic bronchitis, conditions characterized by fluctuating or episodic manifestations linked to thick mucus. The core evidence was evaluated in numerous Randomized Controlled Trials (RCTs), with subsequent large-scale systematic reviews and meta-analyses combining the data. These studies typically involved adults with stable forms of the condition and were conducted over extended periods.

Researchers monitored several key outcomes, including the frequency of acute exacerbations and patient reports of health-related quality of life. Studies monitored the number of acute exacerbations reported by participants and described patterns of differing frequency between the intervention group and the placebo group over the long-term observation period. Research also examined scores in patient-reported quality of life, and findings describe patterns where reported scores were observed in some studies to be higher than those in the placebo group. However, research concerning a measurable, sustained change in how the lungs physically function (such as FEV1) appear to be limited or variable.

Research into Symptom Management and Mucus Properties

Carbocisteine was also studied for short-term outcomes related to physical discomfort in a variety of conditions involving periods of heightened symptoms due to excessive, viscous mucus. Research examined the objective physical properties of mucus itself. Studies monitored patient-reported outcomes describing perceived discomfort, and findings describe patterns where participants reported scores related to ease of expectoration and chest comfort. Research highlights changes measured during the study period in laboratory analysis, where mucus was observed in some studies to have less viscosity and elasticity. The evidence derived from these settings is limited in providing long-term clinical context.

Evidence for Use in Bronchiectasis

Carbocisteine was studied for bronchiectasis, a condition marked by functional limitations. Analysis of key dedicated trials documented mixed findings regarding the outcomes related to episodic or acute changes when compared to placebo in this population. The evidence is limited and inconsistent regarding the ability to differentiate the intervention from placebo concerning the prevention of acute events in this population.

Areas Where Research is Still Developing

One key area where findings were mixed relates to the impact on lung function measures, where studies often failed to report clear, consistent patterns. Additionally, comparative evidence is lacking against other modern therapies. Overall, the evidence highlights what is known—and what is still uncertain—about the consistency of effects across all potential patient groups and long-term scenarios.

Key Studies & References Effect of carbocysteine on pulmonary exacerbation rate in bronchiectasis (CAMEB): a double-blind, randomised, placebo-controlled trial

Frequently Asked Questions (FAQ)

Common questions about Mucoflem (FAQ)


Q: How quickly does Mucoflem typically start working?

According to official pharmacokinetic data, the active ingredient in Mucoflem is quickly absorbed into the body. Peak concentration in the bloodstream is typically reached within approximately 1 to 2 hours after administration. This information helps describe the timeline of absorption, which is key to how the medicine begins working.


Q: What should I expect in terms of how long the effects of Mucoflem last?

Studies examining how the medicine is processed show that the elimination half-life is approximately 2 hours. Because of this, the medicine is generally structured to be taken in divided doses throughout the day to ensure a consistent presence of the active substance and maintain its intended effect.


Q: Does Mucoflem cause drowsiness or make you tired?

Official regulatory documents indicate that Mucoflem is described as having no or negligible influence on a person’s ability to drive or operate machinery. This suggests that the medicine is generally not associated with effects like drowsiness or tiredness that would impair these activities.


Q: Are there any common foods or drinks that should be avoided when taking Mucoflem?

Official guidance in the product labeling states that Mucoflem can be taken with or without food. Furthermore, official information suggests that patients can generally eat and drink normally while using this medicine, as there are no known specific food restrictions.


Q: I'm taking an herbal supplement; could it interact with Mucoflem?

According to authoritative drug information, there is insufficient data available to confirm whether herbal remedies or non-conventional supplements interact with Mucoflem. Official sources note the importance of sharing all information, including use of herbal medicines, with a healthcare professional.


Q: What are the most commonly reported side effects of Mucoflem?

Official regulatory documents describe the known side effects, but many of the adverse reactions, particularly the serious ones, are classified with a frequency of Not Known. This means that based on the available data, the actual rate of occurrence for many effects cannot be accurately estimated or categorized as 'most common' in the official label.


Q: Is Mucoflem available without a prescription in some countries?

The regulatory status of Mucoflem (i.e., whether it requires a prescription or is available over-the-counter) is determined by individual national health authorities. Therefore, its classification varies across different countries and regions globally.


Q: What happens if someone accidentally takes too much Mucoflem?

Official product information suggests that taking an amount exceeding the recommended dose is generally unlikely to cause harm or result in severe symptoms. Nevertheless, in cases of suspected overdose, consultation with a healthcare professional is generally recommended.


Q: Is there a maximum time frame for how long Mucoflem is generally meant to be used?

Regulatory documents reflect that this medicine may be used for a short course in acute symptom management or for long-term supportive therapy in chronic respiratory conditions. The determination of the duration of use rests with the prescribing healthcare provider.


Q: What is the physical appearance of the Mucoflem medicine (pill shape, color, etc.)?

The regulatory description for the capsule formulation indicates that they are typically yellow, size '1' hard gelatin capsules. The internal powder is described as white to off-white granular powder. The oral solution or syrup versions will have different physical properties.


Q: Does Mucoflem have any known effects on the liver or kidneys?

Official regulatory safety information has documented reports of liver dysfunction and jaundice (yellowing of the skin or eyes) as adverse reactions. These effects have been classified with a frequency of 'Not Known' based on available data.


Q: Is there a warning about using Mucoflem before operating machinery or driving?

Regulatory documents state that the medicine has no or negligible influence on the ability to drive or operate machinery. This information is intended to inform patients about the drug's potential for affecting alertness and motor skills.


Q: Does the efficacy of Mucoflem change if it's taken with food?

Official product labeling states that Mucoflem can be taken with or without food. This regulatory guidance suggests that the medicine’s overall efficacy is not substantially dependent on the presence or absence of a meal during administration.


Q: Are there specific warnings for people with diabetes using Mucoflem?

Regulatory labels reflect that diabetes patients may need to consider the excipient content (sugars or substitutes) present in liquid formulations. This careful consideration is necessary for those managing blood glucose levels or with certain hereditary metabolic disorders.


Q: Are there specific instructions regarding alcohol consumption while using Mucoflem?

Official guidance on the use of this medicine indicates that there are generally no specific regulatory restrictions noted regarding alcohol consumption. This information is based on the official product information.


Q: Does Mucoflem have a different effect in children compared to adults?

Official product information notes that different liquid formulations (in terms of strength or concentration) are available and indicated for children compared to adults. The fundamental pharmacological effect of the active substance remains consistent with its description.


Q: Where can I find the official regulatory documents for Mucoflem?

The complete, authoritative regulatory documents (such as the Summary of Product Characteristics or FDA labeling) are published by government agencies responsible for drug approval. These documents are typically made publicly available on the official websites of those national health authorities.


Q: Can Mucoflem be used by people who are vegetarians or vegans?

The capsule formulation contains gelatin, which is an animal-derived product. Suitability for vegetarians or vegans may vary depending on the specific product formulation (capsule vs. liquid), which necessitates a review of the specific product's full list of excipients.


Q: Is Mucoflem gluten-free or lactose-free?

The capsule formulation contains lactose monohydrate, which means this specific form is not lactose-free. Gluten status is generally not a primary focus of regulatory documentation and would necessitate checking the full list of excipients for the specific product being used.

How should Mucoflem be stored and disposed of?

How to Store and Dispose of Mucoflem

Official regulatory documents define strict environmental and access constraints for storing Mucoflem (carbocisteine) to maintain its stability.

Storage & Disposal Scope Official Regulatory Requirement
Temperature Limit Store at a temperature not exceeding 30 C (some labels specify 25 C).
Environmental Protection Must be stored in a dry place, protected from direct light and moisture.
Container Requirement Keep the medicine in its original outer container or packaging and ensure the bottle is tightly closed after use.
Child Safety Must be kept out of the sight and reach of children.
Stability After Opening The oral solution/syrup form has a limited stability period (e.g., 28 days to 6 months, depending on the specific product license) after the initial opening, after which any remainder must be discarded.
Disposal Unused or expired Mucoflem must be discarded according to local pharmaceutical waste programs. Disposal via wastewater or household trash is prohibited to protect the environment.

These requirements, which include maintaining specific temperature ranges and restricting light exposure, define how the product must be stored, protected, handled, and ultimately discarded according to government-approved labeling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Mucoflem found in:

A-Z Index: